GlaxoSmithKline (GSK) has agreed to collaborate with UK-based Adaptimmune to co-develop cancer immunotherapies using its affinity-enhanced T-cell receptor (TCR) engineering technology, including the company’s lead clinical programme targeting the cancer testis antigen NY-ESO-1. GSK will have an option to assume responsibility for the programme through clinical proof-of-concept, which is expected during 2016. The deal, which comes only weeks after GSK agreed to divest its marketed oncology portfolio to Novartis, will complement the company’s ongoing research efforts in the immuno-oncology field.